Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Jenke

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cells|February 12, 2021
Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination TherapyDaniela Gutsch, Robert Jenke, Thomas Büch, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|February 23, 2024
Efficient polymeric nanoparticles for RNAi in macrophage reveal complex effects on polarization markers upon knockdown of STAT3/STAT6Maximilian Walther, Robert Jenke, Achim Aigner, et al.
Cell Death Discovery|August 22, 2025
ERBB3 influences the ferroptosis pathway via modulation of lipid peroxidation and GSH synthesis in gastric cancerRobert Jenke, Theresa Heinrich, Florian Lordick, et al.
Cancers|February 10, 2021
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future PerspectivesRobert Jenke, Nina Reßing, Finn K Hansen, et al.
International Journal of Molecular Sciences|December 30, 2020
SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer CellsRobert Jenke, Miriam Holzhäuser-Rein, Stefanie Mueller-Wilke, et al.
Pharmaceuticals (Basel, Switzerland)|August 29, 2024
Vorinostat Treatment of Gastric Cancer Cells Leads to ROS-Induced Cell Inhibition and a Complex Pattern of Molecular Alterations in Nrf2-Dependent GenesLeoni Lorenz, Tamara Zenz, Denys Oliinyk, et al.
Cancer Research and Treatment|December 12, 2024
The HDAC Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2 Amplified Tumors and in Combination TherapiesTamara Zenz, Robert Jenke, René Thieme, et al.
Neoplasia (New York, N.Y.)|January 26, 2025
Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostatTamara Zenz, Robert Jenke, Denys Oliinyk, et al.
Biochemical Pharmacology|May 5, 2024
HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancerRobert Jenke, Denys Oliinyk, Tamara Zenz, et al.
Chemmedchem|January 24, 2022
Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC InhibitorsLinda Schäker-Hübner, Reza Haschemi, Thomas Büch, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cells|February 12, 2021
Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination TherapyDaniela Gutsch, Robert Jenke, Thomas Büch, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|February 23, 2024
Efficient polymeric nanoparticles for RNAi in macrophage reveal complex effects on polarization markers upon knockdown of STAT3/STAT6Maximilian Walther, Robert Jenke, Achim Aigner, et al.
Cell Death Discovery|August 22, 2025
ERBB3 influences the ferroptosis pathway via modulation of lipid peroxidation and GSH synthesis in gastric cancerRobert Jenke, Theresa Heinrich, Florian Lordick, et al.
Cancers|February 10, 2021
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future PerspectivesRobert Jenke, Nina Reßing, Finn K Hansen, et al.
International Journal of Molecular Sciences|December 30, 2020
SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer CellsRobert Jenke, Miriam Holzhäuser-Rein, Stefanie Mueller-Wilke, et al.
Pharmaceuticals (Basel, Switzerland)|August 29, 2024
Vorinostat Treatment of Gastric Cancer Cells Leads to ROS-Induced Cell Inhibition and a Complex Pattern of Molecular Alterations in Nrf2-Dependent GenesLeoni Lorenz, Tamara Zenz, Denys Oliinyk, et al.
Cancer Research and Treatment|December 12, 2024
The HDAC Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2 Amplified Tumors and in Combination TherapiesTamara Zenz, Robert Jenke, René Thieme, et al.
Neoplasia (New York, N.Y.)|January 26, 2025
Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostatTamara Zenz, Robert Jenke, Denys Oliinyk, et al.
Biochemical Pharmacology|May 5, 2024
HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancerRobert Jenke, Denys Oliinyk, Tamara Zenz, et al.
Chemmedchem|January 24, 2022
Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC InhibitorsLinda Schäker-Hübner, Reza Haschemi, Thomas Büch, et al.
Pageof 1